Cellectis Signs a License Agreement Under Patents Covering Uses of Homologous Recombination With Global Pharmaceutical Company

Regulatory News:

Cellectis (Paris:ALCLS), the genome engineering specialist (Alternext: ALCLS), is announcing that it has signed a license agreement with Novartis for the patents of the family WO 90/11354 covering certain uses of homologous recombination. This technology, which belongs to the Pasteur Institute and for which Cellectis owns exclusive rights, makes it possible to introduce new characteristics into genomes.

Under the terms of this agreement, Cellectis grants to Novartis and its affiliates a non-exclusive license for certain uses of these patents in the field of research and development of therapeutic products.

"This agreement represents further recognition of the quality and relevance of the intellectual property controlled by Cellectis in the Homologous Recombination", confirmed André Choulika, the Cellectis Group's Chairman and CEO. "I am delighted with the start of this relationship with Novartis, which is a major player in the pharmaceutical industry and life sciences sector".

The financial terms of the agreement have not been disclosed.

About Cellectis
Cellectis improves life by applying its genome engineering expertise to a broad range of applications, including human therapeutics, biological research and agriculture. Cellectis is listed on the NYSE-Euronext Paris Alternext market (code: ALCLS).
To find out more, visit www.cellectis.com.

Disclaimer
This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company’s objectives based on the current expectations and assumptions of the Company’s management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.